Abstract
This commentary critically examines a recent study that assessed the effects of metformin and pioglitazone on oxidative stress in patients with type 2 diabetes mellitus. The original study utilized multiple biomarkers such as IMA, TOS, TAS, and OSI but observed only limited antioxidant effects and a rise in IMA levels. By referencing additional clinical trials, experimental studies, and reviews, this commentary emphasizes the importance of using broader biomarker panels, extending treatment duration, and interpreting oxidative stress markers with caution in diabetes research.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.